Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?
Open Access
- 26 September 2011
- journal article
- Published by Springer Nature in Critical Care
- Vol. 15 (5) , R228
Abstract
Introduction: Previous cost-effectiveness analyses (CEA) reported that Drotrecogin alfa (DrotAA) is cost-effective based on a Phase III clinical trial (PROWESS). There is little evidence on whether DrotAA is cost-effective in routine clinical practice. We assessed whether DrotAA is cost-effective in routine practice for adult patients with severe sepsis and multiple organ systems failing. Methods: This CEA used data from a prospective cohort study that compared DrotAA versus no DrotAA (control) for severe sepsis patients with multiple organ systems failing admitted to critical care units in England, Wales, and Northern Ireland. The cohort study used case-mix and mortality data from a national audit, linked with a separate audit of DrotAA infusions. Re-admissions to critical care and corresponding mortality were recorded for four years. Patients receiving DrotAA (n = 1,076) were matched to controls (n = 1,650) with a propensity score (Pscore), and Genetic Matching (GenMatch). The CEA projected long-term survival to report lifetime incremental costs per quality-adjusted life year (QALY) overall, and for subgroups with two or three to five organ systems failing at baseline. Results: The incremental costs per QALY for DrotAA were £30,000 overall, and £16,000 for the subgroups with three to five organ systems failing. For patients with two organ systems failing, DrotAA resulted in an average loss of one QALY at an incremental cost of £15,000. When the subgroup with two organ systems was restricted to patients receiving DrotAA within 24 hours, DrotAA led to a gain of 1.2 QALYs at a cost per QALY of £11,000. The results were robust to other assumptions including the approach taken to projecting long-term outcomes. Conclusions: DrotAA is cost-effective in routine practice for severe sepsis patients with three to five organ systems failing. For patients with two organ systems failing, this study could not provide unequivocal evidence on the cost-effectiveness of DrotAA.Keywords
This publication has 58 references indexed in Scilit:
- Activated protein C in septic shock: a propensity-matched analysisCritical Care, 2011
- Quality of life in the five years after intensive care: a cohort studyCritical Care, 2010
- Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity‐score matched samplesStatistics in Medicine, 2009
- The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomesCritical Care, 2009
- Early drotrecogin alpha (activated) administration in severe sepsis is associated with lower mortality: a retrospective analysis of the Canadian ENHANCE cohortCritical Care, 2009
- Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shockIntensive Care Medicine, 2008
- Evaluating Health Care Programs by Combining Cost with Quality of Life Measures: A Case Study Comparing Capitation and Fee for ServiceHealth Services Research, 2008
- Cost-effectiveness of activated protein C in real-life clinical practiceCritical Care, 2007
- Incidence, treatment, and outcome of severe sepsis in ICU-treated adults in Finland: the Finnsepsis studyIntensive Care Medicine, 2007
- Cost‐effectiveness acceptability curves – facts, fallacies and frequently asked questionsHealth Economics, 2004